New antibody aims to tame rare liver disease
NCT ID NCT04595825
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial tests an experimental antibody drug called CM-101 in adults with primary sclerosing cholangitis (PSC), a rare liver disease. The drug targets a protein called CCL24 to potentially reduce inflammation and scarring. Participants receive either CM-101 or a placebo by intravenous infusion, and researchers monitor safety and signs of disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CM-101 (anti-human CCL24 monoclonal antibody)
- What this could lead to
- If successful, this could point toward a new treatment to control primary sclerosing cholangitis and slow liver damage.
- What could go wrong
- This is an early phase 2 trial with a small number of participants, so results may not confirm effectiveness or safety for wider use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Assuta Medical Center - site P31
Tel Aviv, Israel
-
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital - site P09
Cambridge, United Kingdom
-
Carmel - site P27
Haifa, Israel
-
EMMS Holy Family Nazareth Hospital - site P26
Nazareth, Israel
-
Galilee Medical Center - site P24
Nahariya, Israel
-
Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park - site P82
Germantown, Tennessee, 38138-1741, United States
-
Hadassah Ein Kereme - site P21
Jerusalem, 91120, Israel
-
Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - Liver Center - site P81
Boston, Massachusetts, 02215, United States
-
Hospital Clínic de Barcelona - site P67
Barcelona, 8036, Spain
-
Hospital Universitari i Politècnic La Fe - site P64
Valencia, 46026, Spain
-
Hospital Universitario Miguel Servet - site P65
Zaragoza, 50009, Spain
-
Hospital Universitario Ramón y Cajal - site P61
Madrid, 28034, Spain
-
King's College Hospital NHS Foundation Trust - site P04
London, United Kingdom
-
Klinikum der Johann Wolfgang Goethe-Universitaet - site P42
Frankfurt am Main, Germany
-
Leeds Teaching Hospitals NHS Trust - site P08
Leeds, WYK, LS9 7TF, United Kingdom
-
Massachusetts General Hospital - site P95
Boston, Massachusetts, 02114, United States
-
Medizinische Hochschule Hannover (MHH) - site P41
Hanover, Germany
-
Methodist Dallas Medical Center - site P72
Dallas, Texas, 75203, United States
-
NHS Greater Glasgow and Clyde - site P03
Glasgow, United Kingdom
-
Northwestern University - site P77
Chicago, Illinois, 60611, United States
-
Oxford University Hospitals NHS Foundation Trust- site P11
Oxford, United Kingdom
-
Plymouth Hospitals NHS Trust - Derriford Hospital - site P07
Plymouth, United Kingdom
-
Rambam MC - site P22
Haifa, Israel
-
Scripps Clinic Torrey Pines - site P83
La Jolla, California, 92037, United States
-
Shaarei Tszedek Medical Center - site P29
Jerusalem, Israel
-
Shamir Medical Center (Assaf Harofeh) - site P28
Be’er Ya‘aqov, Israel
-
Soroka MC - site P23
Beersheba, Israel
-
Tel-Aviv Sourasky Medical Center - site P30
Tel Aviv, Israel
-
The Royal Free Hospital - site P01
London, United Kingdom
-
UC Davis Health System - Midtown Ambulatory Care Center - site P79
Sacramento, California, 95816-5202, United States
-
University Hospitals Birmingham NHS Foundation Trust - site P05
Birmingham, United Kingdom
-
Universitätsklinikum Hamburg-Eppendorf (UKE) - site P47
Hamburg, 20246, Germany
-
Virginia Commonwealth - site P94
Richmond, Virginia, 23284, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Could a common drug stop a rare liver disease from returning after transplant?